Could a common sedative calm delirium in End-of-Life cancer care?
NCT ID NCT01949662
First seen Feb 14, 2026 · Last updated May 01, 2026 · Updated 11 times
Summary
This study looks at whether adding lorazepam (a sedative) to haloperidol (a standard antipsychotic) can better reduce delirium—sudden confusion and agitation—in people with advanced cancer. About 90 patients in a palliative care unit will receive either haloperidol alone or haloperidol plus lorazepam. The goal is to see if the combination helps patients feel calmer and more comfortable without causing excessive drowsiness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.